Intravenous valproate in neuropsychiatry

Pharmacotherapy

Volumn 20, Issue 1 I, 2000, Pages 88-92

  Norton, John W ^a,c   Quarles, Emily ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CLONAZEPAM; DIAZEPAM; DRUG; ERYTHROMYCIN; ETHOSUXIMIDE; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; EPILEPTIC STATE; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MALE; NAUSEA; NEUROPSYCHIATRY; PANCREATITIS; SOMNOLENCE; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT INDICATION; VERTIGO; VOMITING;

EID: 0033987513     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.1.88.34657     Document Type: Article

References (37)

1. Anonymous. Valproate sodium injection. In: Physicians' desk reference, 53rd ed. Montvale, NJ: Medical Economics, 1999:417-21.
2. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992;12:42S-52.
3. McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993;38(3 suppl 2):S62-6.
4. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium in the treatment of mania. JAMA 1994;271(12):918-24.
5. Guay DRP. The emerging role of valproate in bipolar disorder and other psychiatric disorders. Pharmacotherapy 1995;15(5): 631-47.
6. Bowden CL, McElroy SL. History of the development of valproate for treatment of bipolar disorder. J Clin Psychiatry 1995;56(suppl 3):3-5.
7. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-6.
8. Puzantian T. Criteria for use of valproate in adult psychiatric inpatients and outpatients. Am J Health-Syst Pharm 1996;53:1187-8.
9. Bowden CL. Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 1996;57(suppl 13):4-9.
10. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54(1):37-42.
11. Grossman F. A review of anticonvulsants in treating agitated, demented, elderly patients. Pharmacotherapy 1998;18(3): 600-6.
12. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998;19:194-9.
13. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998;97(6):387-97.
14. Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998;59(suppl 6):74-81.
15. Walden J, Normann C, Langosch L, et al. Differential treatment of bipolar disorder with old and new antiepileptic drugs. Neuropsychobiology 1998;38(3):181-4.
16. Bowden CL. Introduction: the use of mood stabilizers in the treatment of psychiatric disorders. J Clin Psychiatry 1999;60(suppl 5):3-4.
17. Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999;50:201-13.
18. Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999;156:1264-6.
19. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-71.
20. Naritoku DK, Mueed S. Intravenous loading of valproate for epilepsy. Clin Neuropharmacol 1999;22(2):102-6.
21. Vankataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35(2):147-53.
22. Erfurth A, Grunze H. New perspectives in the treatment of acute mania: a single case report. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1053-9.
23. Hilty DM, Rodriguez GD, Hales RE. Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1998;10:365-6.
24. Grunze H, Erfurth A, Amann B, et al. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 1999;19(4):303-9.
25. Nitsche V, Mascher H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 1982;23:153-61.
26. Bialer M, Hussein Z, Itamer R, et al. Pharmacokinetics of valproic acid in volunteers after a single dose study. BiopharmDrug Dispos 1985;6(1):33-42.
27. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988;15:367-89.
28. Hussein Z, Patterson KJ, Lamm J, et al. Effect of infusion duration on valproate pharmacokinetics. BiopharmDrug Dispos 1993;14(5):389-99.
29. Hussein Z, Mukherjee D, Lamm J, et al. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol 1994;24:754-9.
30. Graves NM, Garnett WR. Epilepsy. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, a pathophysiologic approach, 4th ed. Stamford, CT: Appleton & Lange, 1999:963, 970.
31. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996;153:765-70.
32. Van Valkenburg C, Kluznik J, Merrill R, Erickson W. Therapeutic levels of valproate for psychosis. Psychopharmacol Bull 1990;26(2):254-5.
33. Devinsky O, Leppik I, Willmore LJ, et al. Safety of intravenous valproate. Ann Neurol 1995;38:670-4.
34. Beydoun A, Sackellares JC, Shu V, et al. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy; a double blind concentration-response design clinical trial. Neurology 1997;48:182-8.
35. Jacob PC, Chand RP. Pathological laughter following sodium valproate. Can J Neurol Sci 1998;25:252-3.
36. Wangemann M, Wolf C, Retzow A. Replacement of oral valproate with intravenous valproate: a study on dose finding and bioavailability. Eur J Clin Res 1997;9:209-15.
37. Puentes E, Puzantian T, Lum BL. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit 1999;21(3): 351-4.